Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study)

摘要: Abstract Objective To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients treated for malignant glioma under typical daily practice conditions Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). Materials methods Retrospective review data from 18 neurosurgery departments that were categorised as either or not 5-ALA. The study included adult with suspected gliomas whom the intended treatment plan followed by radiotherapy chemotherapy temozolomide. Postoperative MRI clinical representing least required inclusion. Rates CR PFS6 compared between 5-ALA those without. Results 251 evaluable cases. rates significantly higher group surgically 5-ALA: CR, 67% versus 45%, P = .000; grade IV tumours, 69% 48%; P = .002. differences retained their significance magnitude after adjusting all covariates including age, functional status, whether located eloquent areas. Conclusions In this retrospective series, use during habitual surgical procedures Spain was associated a increased glioma.